NDASUBCUTANEOUSSOLUTION
Approved
Apr 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
14
Data completeness
5/8 — Partial
Drug data last refreshed 12m ago · AI intelligence enriched 12m ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TYMLOS (abaloparatide) is a subcutaneous parathyroid hormone-related peptide (PTHrP) analog approved in 2017 for postmenopausal women with osteoporosis at high fracture risk. It works by mimicking PTHrP signaling to stimulate bone formation and increase bone mineral density. The drug is administered via daily self-injection and represents a distinct mechanism within the osteoporosis treatment landscape.
$0.198BPart D
Peak13.2 years to LOEProduct is at peak revenue stage with modest Medicare utilization; commercial teams are focused on market penetration and account management rather than launch dynamics.
Mechanism of Action
Pharmacologic Class:
Parathyroid Hormone-Related Peptide Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (14)
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
Started Jun 2025
282 enrolled
Postmenopausal Women With Osteoporosis
Supracondylar Distal Femur Fractures and Abaloparatide
Started Jun 2024
0Femoral Fractures
Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women
Started Jul 2021
22,054 enrolled
Osteoporosis, Postmenopausal
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
Started Feb 2021
70 enrolled
Osteoporosis, Postmenopausal
Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.
Started Nov 2020
36 enrolled
Osteoporosis
Worked on TYMLOS at Radius Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.